Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
ConclusionsEarly-stage TNBC might be a target population for olaparib, irrespective of gBRCA mutations. Future trials should combine TILs, PD-L1 and gBRCA status to better identify candidates for escalated/de-escalated treatment strategies including olaparib.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | CT Scan | Gastroschisis Repair | Genetics | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | PET Scan